These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26711769)

  • 1. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors impair antibacterial defenses of macrophages.
    Mombelli M; Lugrin J; Rubino I; Chanson AL; Giddey M; Calandra T; Roger T
    J Infect Dis; 2011 Nov; 204(9):1367-74. PubMed ID: 21921209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
    Li Y; Zhao T; Liu B; Halaweish I; Mazitschek R; Duan X; Alam HB
    J Trauma Acute Care Surg; 2015 Feb; 78(2):378-85. PubMed ID: 25757125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.
    Zhu C; Cai Y; Zhu J; Zhang L; Xing A; Pan L; Jia H; Mo S; Feng CG; Shen H; Chen X; Zhang Z
    Tuberculosis (Edinb); 2019 Sep; 118():101861. PubMed ID: 31526947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 inhibitor promotes reactive oxygen species-meditated clearance of Staphylococcus aureus in macrophage.
    Yimiti M; Fei X; Yang H; Yang X; Li S; Tuoheniyazi H; Liu D; Ma J; Xie J; Zheng J; Song Z; Li Q; Xu D; Zhao Y; Gu Z
    Clin Exp Pharmacol Physiol; 2024 Jun; 51(6):e13866. PubMed ID: 38719209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion.
    Aune SE; Herr DJ; Mani SK; Menick DR
    J Mol Cell Cardiol; 2014 Jul; 72():138-45. PubMed ID: 24632412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities.
    Lkhagva B; Kao YH; Lee TI; Lee TW; Cheng WL; Chen YJ
    Epigenetics; 2018; 13(4):376-385. PubMed ID: 29613828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of Class I Histone Deacetylases (HDAC) by Human Dendritic Cells after Alcohol Consumption and In Vitro Alcohol Treatment and Their Implication in Oxidative Stress: Role of HDAC Inhibitors Trichostatin A and Mocetinostat.
    Agudelo M; Figueroa G; Parira T; Yndart A; Muñoz K; Atluri V; Samikkannu T; Nair MP
    PLoS One; 2016; 11(6):e0156421. PubMed ID: 27249803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances
    Moreira JD; Koch BEV; van Veen S; Walburg KV; Vrieling F; Mara Pinto Dabés Guimarães T; Meijer AH; Spaink HP; Ottenhoff THM; Haks MC; Heemskerk MT
    Front Immunol; 2020; 11():36. PubMed ID: 32117228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
    Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
    Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.